AIBioTech(R) Receives Subcontract Award From DynPort Vaccine Company LLC, for Continued Development and FDA Approval of a Nerve

AIBioTech(R) Receives Subcontract Award From DynPort Vaccine Company LLC, for
Continued Development and FDA Approval of a Nerve Agent Prophylactic

RICHMOND, Va., May 23, 2013 (GLOBE NEWSWIRE) -- AIBioTech is pleased to
announce receipt of a firm fixed price subcontract from DynPort Vaccine
Company LLC (DVC), a CSC company, valued at nearly $3 million for laboratory
studies to support development of a biologic intended for use prior to an
exposure to nerve agents. DVC issued this subcontract under its prime contract
number W911QY-13-C-0056 with the U.S. Department of Defense.

This medical countermeasure (MCM) is intended to decrease incapacitation and
death associated with nerve agent poisoning by binding and inactivating the
nerve agent in the circulatory system before it can reach the nervous system.
The program is intended to deliver a new capability to help soldiers in combat
remain functional following nerve agent exposure and continue performing their

The U.S. Army has been evaluating a naturally occurring enzyme in humans
called butyrylcholinesterase (BuChE) for its potential use as a chemical agent
MCM. Under its previous subcontract to DVC, AIBioTech implemented and then
validated a laboratory assay which measures the activity of BuChE and then
used the assay to assess the enzyme levels in Phase I human clinical trial
samples. The new contract builds on the initial body of work and includes
development of new laboratory assays, new validation studies, qualification of
the BuChE source materials, and assay of human clinical trial samples.

"We are very excited to participate in this program of national import and
significance," said AIBioTech President and Chief Scientific Officer, Dr.
Robert B. Harris. "AIBioTech and DVC have a long collaborative history, and we
are very pleased to re-invigorate this partnership." Added Harris, "The broad
scientific expertise at AIBioTech allows DVC to centralize these necessary
laboratory support activities under one roof with confidence that the work
will be done in a timely and cost conscious manner."

Any opinions, findings and conclusions or recommendations expressed in this
material are those of the author(s) and do not necessarily reflect the views
of the U.S. Department of Defense, Department of the Army, Chemical Biological
Medical Systems Joint Project Management Office (CBMS JPMO), Medical
Identification and Treatment Systems Joint Product Management Office (MITS

About AIBioTech^®

AIBioTech is a comprehensive contract research organization which provides
integrated research and development services and clinical testing to
physicians and life science investigators in biotechnology and pharmaceutical
companies, academic institutions, and in several different government
agencies. Its services are offered individually or can be integrated to
support product development from discovery to market with full regulatory
support. Learn more about AIBioTech at

CONTACT: For further information, contact:
         Dr. Robert B. Harris, President/CSO
         Phone: 804 915 3840
         Fax: 804 915 3830

AIBioTech Logo
Press spacebar to pause and continue. Press esc to stop.